NCT01974765View on ClinicalTrials.gov

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 5, 2013

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Advanced Epithelial OvarianRecurrent Epithelial OvarianFallopian TubePrimary Peritoneal Carcinoma
Interventions
DRUG

Enzalutamide

All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01974765 - Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | Biotech Hunter | Biotech Hunter